Aside from the HDAC inhibitors SAHA and romidepsin, which are approved for the treatment of cutaneous T-cell lymphoma [42, 44, 45], various other HDAC inhibitors are currently undergoing clinical trials for the treatment of different tumors, including lymphomas and solid tumors [42, 44]. The gene discussed is HDAC9; the disease is lymphoma.